• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小RNA-30a抑制卵巢癌中的内皮素A受体及化疗耐药性。

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.

作者信息

Sestito Rosanna, Cianfrocca Roberta, Rosanò Laura, Tocci Piera, Semprucci Elisa, Di Castro Valeriana, Caprara Valentina, Ferrandina Gabriella, Sacconi Andrea, Blandino Giovanni, Bagnato Anna

机构信息

Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Rome, Italy.

Gynecologic Oncology Unit, Catholic University of Rome, Rome, Italy.

出版信息

Oncotarget. 2016 Jan 26;7(4):4009-23. doi: 10.18632/oncotarget.6546.

DOI:10.18632/oncotarget.6546
PMID:26675258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4826186/
Abstract

Drug resistance remains the major clinical barrier to successful treatment in epithelial ovarian carcinoma (EOC) patients, and the evidence of microRNA involvement in drug resistance has been recently emerging. Endothelin-1 (ET-1)/ETA receptor (ETAR) axis is aberrantly activated in chemoresistant EOC cells and elicits pleiotropic effects promoting epithelial-to-mesenchymal transition (EMT) and the acquisition of chemoresistance. However, the relationship between ETAR and miRNA is still unknown. Hence, in this study we evaluated whether dysregulation of miRNA might enhance ETAR expression in sensitive and resistant EOC cells. Based on bioinformatic tools, we selected putative miRNA able to recognize the 3'UTR of ETAR. An inverse correlation was observed between the expression levels of miR-30a and ETAR in both EOC cell lines and tumor samples. miR-30a was found to specifically bind to the 3'UTR of ETAR mRNA, indicating that ETAR is a direct target of miR-30a. Overexpression of miR-30a decreased Akt and mitogen activated protein kinase signaling pathway activation, cell proliferation, invasion, plasticity, EMT marker levels, and vascular endothelial growth factor release. Interestingly, ectopic expression of miR-30a re-sensitized platinum-resistant EOC cells to cisplatinum-induced apoptosis. Consistently, resistant EOC xenografts overexpressing miR-30a resulted in significantly less tumor growth than controls. Together our study provides a new perspective on the regulatory mechanism of ETAR gene. Interestingly, our findings highlight that blockade of ETAR regulatory axis is the mechanism underlying the tumor suppressor function of miR-30a in chemoresistant EOC cells.

摘要

耐药性仍然是上皮性卵巢癌(EOC)患者成功治疗的主要临床障碍,最近有证据表明微小RNA参与了耐药过程。内皮素-1(ET-1)/ETA受体(ETAR)轴在化疗耐药的EOC细胞中异常激活,并引发多效性作用,促进上皮-间质转化(EMT)和获得耐药性。然而,ETAR与微小RNA之间的关系仍不清楚。因此,在本研究中,我们评估了微小RNA的失调是否会增强敏感和耐药EOC细胞中ETAR的表达。基于生物信息学工具,我们选择了能够识别ETAR 3'UTR的假定微小RNA。在EOC细胞系和肿瘤样本中均观察到miR-30a与ETAR的表达水平呈负相关。发现miR-30a特异性结合ETAR mRNA的3'UTR,表明ETAR是miR-30a的直接靶点。miR-30a的过表达降低了Akt和丝裂原活化蛋白激酶信号通路的激活、细胞增殖、侵袭、可塑性、EMT标志物水平以及血管内皮生长因子的释放。有趣的是,miR-30a的异位表达使铂耐药的EOC细胞对顺铂诱导的凋亡重新敏感。一致地,过表达miR-30a的耐药EOC异种移植瘤的肿瘤生长明显低于对照组。我们的研究共同为ETAR基因的调控机制提供了新的视角。有趣的是,我们的发现突出了ETAR调控轴的阻断是miR-30a在化疗耐药EOC细胞中发挥肿瘤抑制功能的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/47fa320c1813/oncotarget-07-4009-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/40f22c5b1129/oncotarget-07-4009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/9a418f5c5ee1/oncotarget-07-4009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/e222965ed72f/oncotarget-07-4009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/01af7263739c/oncotarget-07-4009-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/1281799cf3cd/oncotarget-07-4009-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/266311143aed/oncotarget-07-4009-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/47fa320c1813/oncotarget-07-4009-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/40f22c5b1129/oncotarget-07-4009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/9a418f5c5ee1/oncotarget-07-4009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/e222965ed72f/oncotarget-07-4009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/01af7263739c/oncotarget-07-4009-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/1281799cf3cd/oncotarget-07-4009-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/266311143aed/oncotarget-07-4009-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61b7/4826186/47fa320c1813/oncotarget-07-4009-g007.jpg

相似文献

1
miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.微小RNA-30a抑制卵巢癌中的内皮素A受体及化疗耐药性。
Oncotarget. 2016 Jan 26;7(4):4009-23. doi: 10.18632/oncotarget.6546.
2
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.化学耐药性和 EMT 表型的获得与卵巢癌细胞内皮素 A 受体途径的激活有关。
Clin Cancer Res. 2011 Apr 15;17(8):2350-60. doi: 10.1158/1078-0432.CCR-10-2325. Epub 2011 Jan 10.
3
Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.内皮素 A 受体/β-arrestin 信号转导至 Wnt 通路使卵巢癌细胞对化疗产生耐药性。
Cancer Res. 2014 Dec 15;74(24):7453-64. doi: 10.1158/0008-5472.CAN-13-3133. Epub 2014 Nov 6.
4
Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.马西替坦阻断内皮素-1 受体激活,从而抑制化疗耐药卵巢癌细胞的可塑性和转移。
Life Sci. 2016 Aug 15;159:43-48. doi: 10.1016/j.lfs.2016.01.009. Epub 2016 Jan 8.
5
MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin.MicroRNA-30a 通过靶向 metadherin 抑制乳腺癌的生长和转移。
Oncogene. 2014 Jun 12;33(24):3119-28. doi: 10.1038/onc.2013.286. Epub 2013 Jul 15.
6
Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer.靶向内皮素1受体-miR-200b/c-ZEB1信号通路可抑制卵巢癌的转移进程。
Commun Biol. 2020 Nov 13;3(1):677. doi: 10.1038/s42003-020-01404-3.
7
MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.MicroRNA-302 通过调控卵巢癌细胞中的 ATAD2 抑制上皮-间质转化和顺铂耐药性。
Exp Cell Res. 2020 Nov 1;396(1):112241. doi: 10.1016/j.yexcr.2020.112241. Epub 2020 Aug 21.
8
S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.S100A7 通过 MAPK 信号调节卵巢癌细胞转移和化疗耐药性,并且受 miR-330-5p 靶向调控。
DNA Cell Biol. 2018 May;37(5):491-500. doi: 10.1089/dna.2017.3953. Epub 2018 Feb 27.
9
MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3.微小RNA-29B(mir-29b)通过靶向AKT2和AKT3调控卵巢癌中的瓦伯格效应。
Oncotarget. 2015 Dec 1;6(38):40799-814. doi: 10.18632/oncotarget.5695.
10
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.内皮素-1促进人卵巢癌细胞的上皮-间质转化。
Cancer Res. 2005 Dec 15;65(24):11649-57. doi: 10.1158/0008-5472.CAN-05-2123.

引用本文的文献

1
Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer.卵巢癌治疗策略中用于检测和靶向微小RNA/表观遗传学的不断演变的格局。
Cancer Lett. 2024 Nov 29;611:217357. doi: 10.1016/j.canlet.2024.217357.
2
Endothelin and the tumor microenvironment: a finger in every pie.内皮素与肿瘤微环境:多管齐下。
Clin Sci (Lond). 2024 Jun 5;138(11):617-634. doi: 10.1042/CS20240426.
3
Endothelin-1 and Its Role in Cancer and Potential Therapeutic Opportunities.内皮素-1及其在癌症中的作用和潜在治疗机会。

本文引用的文献

1
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.Wnt/β-连环蛋白信号通路在驱动上皮性卵巢癌铂耐药中的关键作用。
Oncotarget. 2015 Sep 15;6(27):23720-34. doi: 10.18632/oncotarget.4690.
2
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.双重内皮素受体拮抗剂马西替坦与替莫唑胺联合使用可使小鼠胶质母细胞瘤消退并长期存活。
Clin Cancer Res. 2015 Oct 15;21(20):4630-41. doi: 10.1158/1078-0432.CCR-14-3195. Epub 2015 Jun 23.
3
The miR-30 Family Inhibits Pulmonary Vascular Hyperpermeability in the Premetastatic Phase by Direct Targeting of Skp2.
Biomedicines. 2024 Feb 23;12(3):511. doi: 10.3390/biomedicines12030511.
4
Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.预测化疗耐药性——临床前数据如何帮助修改高级别浆液性卵巢癌的治疗策略。
Curr Oncol. 2023 Dec 29;31(1):229-249. doi: 10.3390/curroncol31010015.
5
Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.重新审视卵巢癌的化疗耐药性:机制、生物标志物与精准医学。
Genes Dis. 2020 Dec 1;9(3):668-681. doi: 10.1016/j.gendis.2020.11.017. eCollection 2022 May.
6
MicroRNA-506-3p inhibits ovarian cancer metastasis by down-regulating the expression of EZH2.微小RNA-506-3p通过下调EZH2的表达来抑制卵巢癌转移。
J Cancer. 2022 Jan 4;13(3):943-950. doi: 10.7150/jca.66959. eCollection 2022.
7
The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.miRNA 表达谱及其在顺铂和紫杉醇耐药卵巢癌细胞系中调控耐药基因的潜在作用。
Int J Mol Sci. 2022 Jan 4;23(1):526. doi: 10.3390/ijms23010526.
8
MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.微小 RNA miR-30a 通过自噬抑制卵巢癌细胞对顺铂的耐药性。
Bioengineered. 2021 Dec;12(2):10713-10722. doi: 10.1080/21655979.2021.2001989.
9
Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?子宫内膜异位症相关的卵巢透明细胞癌:一种特殊的实体?
J Cancer. 2021 Sep 23;12(22):6773-6786. doi: 10.7150/jca.61107. eCollection 2021.
10
High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome.高 miR-30 表达与乳腺癌患者生存率提高及治疗结果改善相关。
Cancers (Basel). 2021 Jun 10;13(12):2907. doi: 10.3390/cancers13122907.
miR-30 家族通过直接靶向 Skp2 抑制前转移期肺血管高通透性。
Clin Cancer Res. 2015 Jul 1;21(13):3071-80. doi: 10.1158/1078-0432.CCR-14-2785. Epub 2015 Mar 25.
4
Dysregulation of microRNA biogenesis and gene silencing in cancer.癌症中微小RNA生物合成与基因沉默的失调
Sci Signal. 2015 Mar 17;8(368):re3. doi: 10.1126/scisignal.2005825.
5
miR30a inhibits LOX expression and anaplastic thyroid cancer progression.miR30a 抑制 LOX 表达和间变性甲状腺癌进展。
Cancer Res. 2015 Jan 15;75(2):367-77. doi: 10.1158/0008-5472.CAN-14-2304. Epub 2014 Dec 8.
6
Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.内皮素 A 受体/β-arrestin 信号转导至 Wnt 通路使卵巢癌细胞对化疗产生耐药性。
Cancer Res. 2014 Dec 15;74(24):7453-64. doi: 10.1158/0008-5472.CAN-13-3133. Epub 2014 Nov 6.
7
MicroRNAs as prognostic markers in ovarian cancer.微小RNA作为卵巢癌的预后标志物
Mol Cell Endocrinol. 2014 Jun 5;390(1-2):73-84. doi: 10.1016/j.mce.2014.03.006. Epub 2014 Apr 18.
8
RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells.在胃癌细胞上皮-间质转化过程中,RUNX3通过miR-30a调节波形蛋白的表达。
J Cell Mol Med. 2014 Apr;18(4):610-23. doi: 10.1111/jcmm.12209. Epub 2014 Jan 22.
9
Endothelin 1 in cancer: biological implications and therapeutic opportunities.内皮素 1 在癌症中的作用:生物学意义及治疗机会。
Nat Rev Cancer. 2013 Sep;13(9):637-51. doi: 10.1038/nrc3546. Epub 2013 Jul 25.
10
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.一个 microRNA 特征通过调节血管生成来定义卵巢癌的化疗耐药性。
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9845-50. doi: 10.1073/pnas.1305472110. Epub 2013 May 22.